Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy

2024-9-12

CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

2024-8-27

Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma

2024-8-26

Metabolic regulation of the mitochondrial immune checkpoint

2024-8-26

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade

2024-8-22

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

2024-8-22

Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, <i>SOX2</i> , and <i>CD44</i> through NFκB-signaling

2024-8-21

<i>FCGR3A</i> F158V alleles frequency differs in multiple myeloma patients from healthy population

2024-8-18

Correction

2024-8-11

Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

2024-8-10

Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma

2024-8-9

DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma

2024-8-5

Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

2024-7-27

Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells

2024-7-27

CXCR1/2 antagonism inhibits neutrophil function and not recruitment in cancer

2024-7-26

S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs

2024-7-24

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

2024-7-18

Human NK cells and cancer

2024-7-16

Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment

2024-7-10

SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion

2024-7-9

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

2024-7-9

Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes

2024-7-8

Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes

2024-7-4

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden

2024-7-3

<i>Faecalibacterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitors

2024-7-1

Candidate tumor-specific CD8 ⁺ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis

2024-6-28

Complete response of metastatic microsatellite-stable <i>BRAF</i> V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

2024-6-28

Identification of RNA-binding protein hnRNP C targeting the 3’UTR of the TAP-associated glycoprotein tapasin in melanoma

2024-6-27

CD161 ⁺ CD127 ⁺ CD8 ⁺ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus

2024-6-27

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity

2024-6-27

Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients

2024-6-26

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

2024-6-24

Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses

2024-6-21

ADA/CD26 axis increases intra-tumor PD-1 ⁺ CD28 ⁺ CD8 ⁺ T-cell fitness and affects NSCLC prognosis and response to ICB

2024-6-21

Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models

2024-6-20

ALCAM-mediated cDC1 CD8 T cells interactions are suppressed in advanced lung tumors

2024-6-14

CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent

2024-6-14

Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34

2024-6-11

Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer

2024-6-10

HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer

2024-6-5

β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers

2024-6-4

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

2024-6-4

Immunogenic oncolysis by tigilanol tiglate

2024-5-27

Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma

2024-5-27

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival

2024-5-24

Peripheral CX3CR1 ⁺ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer

2024-5-22

HIF2A mediates lineage transition to aggressive phenotype of cancer-associated fibroblasts in lung cancer brain metastasis

2024-5-20

CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage

2024-5-10

Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors

2024-5-10

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

2024-5-9